Evidence map›Paper›PMID 42890637›Full record

ArticleRSC advances2026

Rationally designed tunable amphiphilic glycopolymers for safe and effective vaccine adjuvanticity.

Aaron T Hendricksen, Luis Ontiveros-Padilla, Connor T Murphy, Grace L Williamson, Alexandra M Lopez, Eric M Bachelder, Kristy M Ainslie

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aaron T HendricksenDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina 4012 Marsico Hall, 125 Mason Farm Road Chapel Hill NC USA ainsliek@email.unc.edu.
Luis Ontiveros-PadillaDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina 4012 Marsico Hall, 125 Mason Farm Road Chapel Hill NC USA ainsliek@email.unc.edu.
Connor T MurphyDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina 4012 Marsico Hall, 125 Mason Farm Road Chapel Hill NC USA ainsliek@email.unc.edu.
Grace L WilliamsonDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina 4012 Marsico Hall, 125 Mason Farm Road Chapel Hill NC USA ainsliek@email.unc.edu.
Alexandra M LopezDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina 4012 Marsico Hall, 125 Mason Farm Road Chapel Hill NC USA ainsliek@email.unc.edu.
Eric M BachelderDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina 4012 Marsico Hall, 125 Mason Farm Road Chapel Hill NC USA ainsliek@email.unc.edu.
Kristy M AinslieDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina 4012 Marsico Hall, 125 Mason Farm Road Chapel Hill NC USA ainsliek@email.unc.edu.ORCID https://orcid.org/0000-0002-1820-8382

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
CAROLINA CANCER NANOTECHNOLOGY TRAINING PROGRAM (C-CNTP)T32CA196589 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Gaorav P. Gupta, ALEXANDER V KABANOV · 2015 to 2026
$4.5M
Mechanistic evaluation of mast cell agonists combined with TLR, NOD and STING agonists.R01AI167099 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Kristy M Ainslie · 2023 to 2026
$2.5M
Request for a 500 MHz NMR console and nitrogen-cooled cryoprobeS10OD032476 · OD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LEE, ANDREW L · 2022 to 2022
$599k
NCI NIH HHS P30 CA016086NCI NIH HHS T32 CA196589NIAID NIH HHS R01 AI167099NIH HHS S10 OD032476
6 · The paper itself

Abstract

Vaccine adjuvants require specific molecular cues to effectively replicate pathogen-derived immunostimulatory signals. Among these, carbohydrate-lipid motifs found on the mycobacterial cell wall are particularly potent targets, as they engage C-type lectin receptors (CLRs) to drive specific Th1/Th17-skewed immunity. To explore this potential, amphiphilic glycopolymers integrating trehalose and long-chain lipid motifs were synthesized to investigate how the covalent co-display of carbohydrate and lipid cues modulates polymer self-assembly and immune activation. By deconstructing the CLR agonist trehalose-6,6'-dibehenate (TDB) into trehalose and behenyl methacrylate monomers, we created a modular platform that overcomes the hydrophobicity and fixed stoichiometry of the parent glycolipid. This strategy presents carbohydrate and lipid signals in close molecular proximity on a single polymer scaffold. A series of well-defined random copolymers comprising trehalose methacrylate and behenyl methacrylate were prepared

Identifiers

PMID42890637
PMCPMC13674014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.